BioCryst Pharmaceuticals ... (BCRX)
El precio, las cifras principales y las últimas noticias, en un solo sitio.
BioCryst Pharmaceuticals Inc. (BCRX): cotización, análisis y datos
No hay datos disponibles
| Precio de compra | 8.36 |
| Capitalización de mercado | 2.47B |
| Ingresos (TTM) | 940.61M |
| Beneficio neto (TTM) | -384.67M |
| 0.55 | |
| -1.38 | |
| n/a | |
| 10.3 | |
| P/B (TTM) | -5.44 |
| P/S (TTM) | 2.63 |
| Fecha de resultados | May 5, 2025 |
| Precio de venta | 10.97 |
| Volumen | 2,010,170 |
| Volumen medio (20D) | 4,449,495 |
| Abierto | 9.50 |
| Anterior Cerrar | 9.55 |
| Rango del día | 9.49 - 9.76 |
| Rango de 52 semanas | 6.00 - 11.22 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a prote...
Desempeño financiero
En 2025, los ingresos de BioCryst Pharmaceuticals fueron 874.84M, un aumento de 94.1% en comparación con 450.71M del año anterior. Las ganancias fueron 263.86M, una disminución de -396.87%.
Estados financierosSorpresa de resultados
- Ingresos de $218.25M falla las estimaciones por $0, con 33.61% Crecimiento interanual.
- EPS de 0.35 supera las estimaciones en 0.11, con 775.00% Crecimiento interanual.
Los analistas proyectan ingresos de ... Actualizar
1 semana hace · Simply Wall St.
Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update?BioCryst Pharmaceuticals (BCRX) is back in focus after raising its full year 2026 revenue outlook, reporting detailed second quarter earnings, and highlighting progress across its hereditary angioedem...
1 semana hace · Simply Wall St.
BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% GainBioCryst Pharmaceuticals stock has put up a 53.0% gain over the past three years, yet the current valuation checks still lean on the inexpensive side for this kind of run. That mix raises the question...
